Blurbs

Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Illumina (ILMN) and Regeneron (REGN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Avadel Pharmaceuticals (AVDLResearch Report), Illumina (ILMNResearch Report) and Regeneron (REGNResearch Report).

Avadel Pharmaceuticals (AVDL)

Needham analyst Ami Fadia maintained a Buy rating on Avadel Pharmaceuticals today and set a price target of $8.00. The company’s shares closed last Thursday at $6.87.

According to TipRanks.com, Fadia is a 2-star analyst with an average return of -0.7% and a 43.9% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Intra-Cellular Therapies, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on Avadel Pharmaceuticals is a Moderate Buy with an average price target of $10.17.

See Insiders’ Hot Stocks on TipRanks >>

Illumina (ILMN)

In a report released today, Dan Leonard from Credit Suisse maintained a Hold rating on Illumina, with a price target of $225.00. The company’s shares closed last Thursday at $211.93, close to its 52-week low of $173.45.

According to TipRanks.com, Leonard is a 5-star analyst with an average return of 10.3% and a 58.4% success rate. Leonard covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Adaptive Biotechnologies, and Bio-Rad Laboratories.

Currently, the analyst consensus on Illumina is a Moderate Buy with an average price target of $256.00, a 22.1% upside from current levels. In a report released today, Robert W. Baird also maintained a Hold rating on the stock with a $210.00 price target.

Regeneron (REGN)

SVB Securities analyst David Risinger maintained a Hold rating on Regeneron today and set a price target of $770.00. The company’s shares closed last Thursday at $738.68, close to its 52-week high of $764.59.

According to TipRanks.com, Risinger is a 4-star analyst with an average return of 14.1% and a 78.6% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Theravance Biopharma, and Horizon Therapeutics.

Currently, the analyst consensus on Regeneron is a Moderate Buy with an average price target of $805.74, implying a 11.0% upside from current levels. In a report issued on October 20, Cowen & Co. also maintained a Hold rating on the stock with a $750.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AVDL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More